Bimagrumab

Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors (ActRIIA and ActRIIB), preventing the muscle-inhibiting effects of myostatin, activins, and GDF11. By blocking the receptor rather than the ligands, it provides comprehensive inhibition of the negative regulatory pathway that limits muscle growth.

The TGF-beta superfamily members myostatin and activins bind to ActRII receptors on muscle cells, activating Smad signaling that suppresses muscle protein synthesis and promotes protein breakdown. Bimagrumab's receptor blockade releases this brake, allowing enhanced muscle hypertrophy and reduced muscle wasting.

Clinical research has demonstrated bimagrumab significantly increases lean body mass while decreasing fat mass, a combination termed 'body recomposition' that is difficult to achieve with other interventions. Studies in sarcopenia, sporadic inclusion body myositis, and obesity have shown these dual effects on body composition.

Particularly intriguing is bimagrumab's potential to preserve or increase muscle mass during weight loss, addressing the muscle loss that typically accompanies caloric restriction and GLP-1 agonist therapy. Research combining bimagrumab with metabolic interventions explores this muscle-sparing application.